Previous 10 | Next 10 |
RMAT Designation Follows Proof-of-Concept Data from ALLO-715 UNIVERSAL Trial in Heavily Pretreated, Refractory Multiple Myeloma Patients UNIVERSAL Trial Demonstrated for the First Time that an Allogeneic CAR T Therapy Directed at BCMA Can Achieve Clinical Responses While Eliminating...
The FDA has cleared an Investigational New Drug ((IND)) application of Allogene Therapeutics (ALLO) to study ALLO-605 for the treatment of patients with relapsed or refractory multiple myeloma.ALLO-605 is part of the company’s multi-faceted strategy to develop an allogeneic CAR T thera...
TurboCAR Technology Allows a Programmable Cytokine Signaling to Potentially Control T Cell Exhaustion and Improve Function and Potency of AlloCAR T™ Cells Phase 1 IGNITE Trial Expected to Begin in Mid-2021 ALLO-605 is One of Allogene’s Three Strategies to Target...
Immunocore is a "platform" pharmaceutical company looking to help naïve T cells recognize and kill their targets. Their technology involves soluble TCRs that recognize markers that indicate whether a cell is cancerous or infected with a virus. Their lead asset, tebentafusp, i...
Allogene Therapeutics (ALLO) and SpringWorks Therapeutics (SWTX) announce that the first patient has been dosed in a Phase 1 trial evaluating the company's investigational anti-B-cell maturation antigen ((BCMA)) AlloCAR T therapy, in combination with nirogacestat in patients with relapse...
SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn., April 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, and Spri...
Proprietary TurboCAR Technology Platform Allows Cytokine Activation Signaling to be Selectively Engineered into AlloCAR T™ Cells New TurboCAR Constructs Can Be Induced by Binding To PDL1/2, Making Cytokine Activation Dependent Upon the Tumor Microenvironment and Overcoming...
Allogene is a world leader in allogeneic CAR-T. Since my last article, the stock has seen some appreciation. ALLO is shaping up to be a good investment. For further details see: Allogene: World Leader In Allogeneic CAR-T
Allogene Therapeutics, Inc. (ALLO) Q4 2020 Earnings Conference Call February 25, 2021 5:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and Chief Executive Officer Rafael Amado - Executive Vice President-Research and Development and Chie...
Presented Initial Phase 1 UNIVERSAL Trial Data on ALLO-715 at The American Society of Hematology (ASH) Meeting Providing First Proof-of-Concept for an AlloCAR T™ Therapy in Relapsed/Refractory Multiple Myeloma Updated ALLO-501 and Initial ALLO-501A AlloCAR T Data in Non-Hodgkin...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in th...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...